Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.99
Cardlytics, Inc. reported Q1 2026 results: revenue $34.3 million, net income $(4.5) million, EPS $(0.08) per diluted share.
- Period
- Q1 2026
- Revenue
- $34.3 million
- Net income
- $(4.5) million
- EPS
- $(0.08) per diluted share
- Result
- reported results
Exact text from the filing
Revenue was $34.3 million, a decrease of 39% year-over-year compared to $56.4 million in the first quarter of 2025. • Billings, a non-GAAP metric, was $58.1 million, a decrease of 37% year-over-year compared to $92.1 million in the first quarter of 2025. • Adjusted Contribution, a non-GAAP metric, was $19.7 million, a decrease of 28% year-over-year compared to $27.3 million in the first quarter of 2025. • Net Loss was $(4.5) million, or $(0.08) per diluted share, based on 54.9 million fully diluted weighted-average common shares, compared to a Net Loss of $(13.3) million, or $(0.26) per diluted share, based on 51.9 million fully diluted weighted-average common shares in the first quarter of 2025.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.98
Cardlytics, Inc. reported Q2 2026 results: revenue $35.0 - $40.0 million. Guidance initiated.
- Period
- Q2 2026
- Revenue
- $35.0 - $40.0 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Cardlytics anticipates Billings, Revenue, Adjusted Contribution and Adjusted EBITDA to be in the following ranges (in millions, except for percentage change rates): Q2 2026 Guidance YoY Change Billings (1) $61.0 - $67.0 (38%) - (32%) Revenue $35.0 - $40.0 (40%) - (31%) Adjusted Contribution (2) $20.0 - $23.0 (36%) - (27%) Adjusted EBITDA (2) ($2.7) - $1.3 ($5.7) - ($1.7)
View on SEC.gov